Pfizer Inc. andBioNTech SE said the Covid-19 vaccine they are jointly developing is on track for regulatory review as early as October, as they released additional data from an early-stage study.
The companies said the vaccine was well tolerated with mild to moderate fever in less than 20% of participants. The companies continue to analyze data from Phase 1 trials in the United States and Germany, they said in adeclaration.
Confirmation of their October goal firstannounced last month, helped lift S&P 500 futures briefly on Friday as part of a drumbeat of positive news on inoculation efforts that have the potential to end the threat of damaging lockdowns.
The schedule would make the vaccine one of the fastest in the world. Some analystsExpect a vaccine to be approved for use by November in the United States, a move that could give President Donald Trump a new foothold in the election.
Pfizer and BioNTech reached a $ 2 billion deal last month to deliver 100 million initial doses of the vaccine to the U.S. Governments around the world are seeking to block the supply of still experimental candidates of the vaccine. hope to stabilize local economies and stop the spread of the virus which has claimed nearly 800,000 lives worldwide.
The US Food and Drug Administration is tentativelyplanning for an advisory committee to meet on October 22 to discuss a Covid-19 vaccine, although it did not specify which vaccines, or how many, will be reviewed.
Some of the rapid efforts around the world have started to assess efficacy at the final stage of testing, paving the way for regulatory approval. Russia approved a vaccine dubbed Sputnik V earlier this month, developed by the Gamaleya Institute in Moscow and Russia’s Sovereign Direct Investment Fund, and plans to administer it widely in October, though the vaccine is still being tested on humans. The movement drewscientists’ criticism of the fear of massive inoculation when the drug’s safety profile remains uncertain.
Vaccine pioneers in China have shipped their vaccines to virus hotspots around the world like Brazil, Indonesia and Saudi Arabia to conduct end-stage trials. Manufacturer of state-owned drugsSinopharm Group Co. said this week that the two inactivated vaccines developed by the company’s subsidiaries will be available by the end of the year and will cost less than 1,000 yuan ($ 145) for two doses. Beijing-based vaccine manufacturerSinovac Biotech Ltd. expects its shot to gain regulatory approval early next year.
– With the help of Sharon Chen and Dong Lyu
(Updates with the context of the sixth paragraph)